TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Biophytis SA ( (FR:ALBPS) ) has issued an announcement.
Biophytis SA announced promising results from its Phase II SARA-INT study for its drug candidate BIO101, which showed significant clinical improvement in sarcopenia patients. The company is preparing to transition to Phase III trials and is in discussions with international partners, highlighting its leadership in addressing the unmet need for sarcopenia treatments.
More about Biophytis SA
Biophytis SA is a clinical-stage biotechnology company focused on developing treatments for age-related diseases. The company’s primary drug candidate, BIO101, is in development for muscle diseases such as sarcopenia and Duchenne muscular dystrophy, as well as respiratory and metabolic conditions. Biophytis is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil.
YTD Price Performance: -16.29%
Average Trading Volume: 7,225
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €4.44M
See more insights into ALBPS stock on TipRanks’ Stock Analysis page.